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ABSTRACT
Previous studies showed that loss of tumornecrosis factora (TNFa) signalingdelayed fracture healingbydelaying chondrocyte apoptosis
and cartilage resorption. Mechanistic studies showed that TNFa induced Fas expression within chondrocytes; however, the degree to
which chondrocyte apoptosis ismediated by TNFa alone or dependent on the inductionof Fas is unclear. This questionwas addressed by
assessing fracture healing in Fas‐deficient B6.MRL/Faslpr/J mice. Loss of Fas delayed cartilage resorption but also lowered bone fraction in
the calluses. The reduced bone fraction was related to elevated rates of coupled bone turnover in the B6.MRL/Faslpr/J calluses, as
evidenced by higher osteoclast numbers and increased osteogenesis. Analysis of the apoptotic marker caspase 3 showed fewer positive
chondrocytes and osteoclasts in calluses of B6.MRL/Faslpr/J mice. To determine if an active autoimmune state contributed to increased
bone turnover, the levels of activated T cells and Treg cellswere assessed. B6.MRL/Faslpr/Jmice had elevated Treg cells in both spleens and
bones of B6.MRL/Faslpr/J but decreased percentage of activated T cells in bone tissues. Fracture led to30% to 60% systemic increase in
Treg cells in bothwild‐type and B6.MRL/Faslpr/J bone tissues during the period of cartilage formation and resorption but either decreased
(wild type) or left unchanged (B6.MRL/Faslpr/J) the numbers of activated T cells in bone. These results show that an active autoimmune
state is inhibited during the period of cartilage resorption and suggest that iTreg cells play a functional role in this process. These data
show that loss of Fas activity specifically in chondrocytes prolonged the life span of chondrocytes and that Fas synergized with TNFa
signaling tomediate chondrocyte apoptosis. Conversely, loss of Fas systemically led to increased osteoclast numbers during later periods
of fracture healing and increased osteogenesis. These findings suggest that retention of viable chondrocytes locally inhibits osteoclast
activity or matrix proteolysis during cartilage resorption. © 2014 The Authors. Journal of Bone and Mineral Research published by Wiley
Periodicals, Inc. on behalf of the American Society for Bone and Mineral Research. This is an open access article under the terms of the
Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the
original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
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Introduction
Studies of the role of TNFa in fracture healing have demons-trated that the expression of TNFa acutely increases during
the inflammatory period (within the first 3 days after injury).
Subsequently during the initial periods of active cartilage
formation, the expression of TNFa and its receptors are almost
absent, but then they reemerge as the cartilage undergoes
resorption. As resorption proceeds, the key regulatory factors in
osteoclastogenesis, receptor activator of NF‐kB ligand (RANKL)
and osteoprotegerin (OPG) (two other members in the TNF
superfamily), as well as macrophage colony‐stimulating factor
(M‐CSF) all become elevated.(1,2) We have also shown that TNF
receptor signaling appeared to coordinate aspects of cartilage
resorption and primary bone remodeling with angiogenesis.(3)
Studies assessing the functional role of TNFa signaling in fracture
healing using transgenic mice deficient in TNFRSF1A and
TNFRSF1B knockout mice demonstrated that there are three
biological processes by which the absence of TNF signaling
affects the progression of fracture healing: 1) a delay in the initial
healing phase, in either recruitment of mesenchymal cells or the
initiation of these cells to undergo skeletogenic cell differentia-
tion; 2) a delay in chondrocyte apoptosis during the period of
endochondral bone formation; and 3) a delay in the resorption in
the mineralized cartilage during the endochondral period.(2) In
summary, a comparison of these various data sets suggests that
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TNFa signaling plays a crucial role in promoting postnatal bone
repair through the recruitment or induction of skeletal cell
progenitors,(4,5) carries out a primary role in the regulation of
chondrocyte apoptosis,(2,6) and plays a role in regulating the
production of factors that control the resorption and vasculari-
zation of mineralized cartilage.(3)
In our analysis of the mechanisms by which TNF receptor
signaling affected fracture healing, we showed that TNFRs
induced the expression of multiple members of the larger TNF
family of ligands and TNF receptors, including Fas, TRAIL, VEGI, and
OPG.(6) Fas ligand (FasL) is unique among these family members
because it binds only to Fas receptor and appears to be primarily
involved in mediating apoptosis.(7) Although Fas and FasL play
specific functional roles in immune cell differentiation,(8,9) Fas also
has been shown to mediate osteoclast apoptosis and loss of
estrogen leads to prolongation of an osteoclast’s life span, which
contributes to sex hormone–dependent osteoporosis.(10,11)
Interestingly, the Fas receptor and its ligand were found to be
uniquely expressed during chondrocyte hypertrophy.(12,13) Fas
has been found in osteoarthritic cartilage, and treatment of
human articular chondrocytes with Fas ligand in vitro causes
apoptosis.(14) During development, Fas system has been shown
to be present in growth plate chondrocytes in vivo(13,15) which
has led to the suggestion that Fas plays a role in chondrocyte
apoptosis during endochondral development. We have shown
that within the fracture callus, chondrocytes express Fas(2) and
that TNFa will induce Fas expression in both repair and articular
chondrocytes.(6,13,16,17) Thus, both TNFa and Fas have been
implicated in providing death signals to chondrocytes. TNFa
promotes apoptosis of both hypertrophic and nonhypertrophic
chondrocyte populations through both Fas‐ and TNFa‐mediated
signaling, whereas articular chondrocytes undergo apoptosis in
response to TNFa.(6,17)
The aforementioned studies on the role of TNFa in fracture
healing and in articular cartilage suggested that TNFa facilitates
apoptosis of chondrocytes through two distinct processes, a
direct induction of apoptosis by TNFa itself and an indirect effect
produced by the upregulation of Fas expression.(6,17) Because
both TNFRs and Fas can mediate apoptosis and their ligands
work in a complex microenvironment in which hematopoietic
and mesenchymal cell populations interact with each other, a
mechanistic understanding of these two proteins’ function will
only come from sorting out how TNF and Fas receptors
coordinate their activities to keep in balance the progression
of apoptosis while promoting skeletal tissue repair after injury. To
assess the effects of Fas separate from TNF receptor signaling
during fracture healing, we examined fracture healing in B6.MRL/
Faslpr/J mice, which have an inactivating mutation in Fas. These
mice develop a generalized lymphoproliferative syndrome and
have been used as a model of Systemic Lupus Erythematosus
(SLE) because they both produce auto‐antibodies and immune‐
mediated glomerulonephritis.(18–20) Thus, our studies will also
present an opportunity to assess how a systemic autoimmune
SLE like pathology will effect fracture healing.
Materials and Methods
Mouse strain
All animal research was conducted under an IACUC‐approved
protocol in conformity with all federal and USDA guidelines. For
these studies, we used mice in which the lpr mutation had been
bred onto the C57/BL/6 strain (B6.MRL‐Faslpr/J) (Jackson Research
Laboratories, Bar Harbor, ME, USA). The choice of strain
backgrounds was based on two separate considerations. The
first was that a C57/BL/6 background allowed direct comparisons
with our previous studies of the TNFRSF1A‐/‐ TNFRSF1B‐/‐
mice.(2) The second consideration was that the lpr mutation in
the MRL background manifests a much greater severity of
lymphadenopathy(21) with an onset as early as 8 weeks, which
could confound our fracture studies. In contrast, the B6.MRL‐
Faslpr/J show onset of the lupus‐like syndrome after 15 weeks.(22)
Generation of femur fractures
All studies were performed on male 8‐ to 10‐week‐old mice.
Unilateral midshaft femoral fractures were produced in the left
femur as previously described.(23) The location and quality of
fractures as well as the position of the intramedullary spinal
needle that was used to fix the fracture were assessed while
animals were still anesthetized using a standard X‐ray machine.
(Sirona, Inc., Charlotte, NC, USA). Fractures that were found to be
profoundly displaced or comminuted were excluded.
Specimen harvests and sample sizes
Animals were euthanized by CO2 asphyxiation. Six fractured
femora from each strain were harvested on each of days 0, 3, 5,
10, 14, 21, and 28 for RNA extraction and molecular analysis.
Three calluses were used to make duplicate pools of mRNAs for
analysis. Eight to 11 fractured femora from each strain were
collected on days 21 and 35 for micro‐computed tomography
(CT) and mechanical testing. Five fractured femora from each
strain were harvested on days 14 and 21 for histological
assessment. Samples for each type of analysis were harvested
and prepared as previously described.(23) Five fractured and
nonfractured femora from each strain were harvested on days 0
and 10 for flow cytometric analysis.
Quantitative micro‐CT
Immediately before scanning, individual femora were removed
from storage and allowed to thaw to room temperature. Bones
were then prepared for scanning by removal of the intra-
medullary pins. Scans were preformed using a Scanco mCT 40
system (Scanco Medical, Bruttisellen, Switzerland). Calluses were
scanned ex vivo at a resolution of 12m/voxel. Scanning protocols
and initial image‐processing methods (reconstruction, noise
reduction) were as described previously.(24) The phenotypic
properties that were quantified were total callus volume (TV),
total mineralized callus volume (BV), mineralized callus volume
fraction (BV/TV), average tissue mineral density (TMD), standard
deviation of the tissue mineral density (TMD), and callus mineral
content (BMC). Calculation of TMD, TMD, and BMC were made
possible by density calibration data obtained from scans of a
hydroxyapatite phantom provided by the CT system manufac-
turer. Based on prior studies, both TMD and TMD were calculated
using only the image voxels whose intensity (gray value)
exceeded a 45% threshold that distinguishes mineralized tissue
from unmineralized and poorly mineralized tissue.(24)
Mechanical testing
After CT scanning, calluses were subjected to biomechanical
testing at the specified days as previously described.(24) All
specimen preparation and testing was performed blind. Speci-
mens were kept frozen at –20°C until right before they were
prepared for torsional testing. Just before testing, the proximal
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and distal ends of the bone were potted in polymethylmetha-
crylate (PMMA). The gage length (exposed length between the
potted ends) wasmeasured at 90° intervals around the specimen
circumference. Torque (torsional moment) was applied to the
specimen, via the aluminum casings, at a rate of 1°/s to failure
using amicrotorsion testing system (55MT1; Instron Corporation,
Canton, MA, USA) equipped with 0.225 N‐m torque transducer to
measure torque and a high‐resolution (0.168 arc‐min) internal
RVDT to measure angular displacement (twist). Data from both
transducers were recorded at a rate of 50 Hz. From the resulting
torque‐twist curve, the maximum torque, torsional rigidity, and
work to failure were calculated.(24)
Demineralized histomorphometry and
immunohistochemistry analysis
Tissue retrieval, fixation, demineralization, and sectioning were
as previously described.(25) The histomorphometric assessment
of osteoclast numbers was based on tartrate‐resistant acid
phosphatase (TRAP) staining with osteoclast cell counts per mm2
surface area.(26) Antibody staining was carried out at the Boston
University Immuno‐histochemistry Core facility using an auto-
mated slide stainer (IntelliPATH FLX System, BioCare Medical,
Inc., Concord, CA, USA). Antigen retrieval was done with trypsin
for 15minutes, and the slides were blockedwith 10% goat serum
and Rodent M blocking IgG for 2 hours. For immunohistochem-
istry, sections were incubated with rabbit polyclonal primary
antibodies against Caspase 3 obtained from Cell Signaling
Technology Inc. (Danvers, MA, USA) at 1:200 dilution for 2 hours
at 4°C. Secondary reactions were carried out using Alexa Fluor
488 Goat Anti‐Rabbit IgG (Hþ L) from Invitrogen Inc. (Carlsbad,
CA, USA) at a dilution of 1:500, and reactions were for 1 hour at
room temperature. DAPI was obtained as ProLong Gold reagent
liquid mountant from Invitrogen Inc. Slides were then washed in
TBST for 2 minutes. All photomicrograph images were taken and
collected on an Olympus Microscopy System (Olympus America
Inc., 3500 Corporate Pkwy, Center Valley, PA, USA) using a Blue
(DAPI): Chroma 31000v2 Green (Immunofluorescense): Chroma
41028 Red (TRAP): Chroma 49005 filter.
Messenger RNA analysis
Total RNA samples were assessed in a duplicate set of pooled
samples prepared from three to four fractured calluses harvested
on 3, 5, 10, 14, 21, and 28 days after fracture. Reference RNA was
prepared from a duplicate set of pooled samples prepared from
three to four 5‐mm segments of unfractured mid‐diaphyseal
femurs. Total RNA was extracted and purified as described by
Wang and colleagues.(27) The two pools of mRNA samples were
then used for each mRNA analysis, which was carried out three
times for each pool of RNA. Ribonuclease protection assays (RPA)
were carried out as described by Cho and colleagues,(28) using
3mg to 10mg of total mRNA dependent on the template set. All
template sets included GAPDH and L32 probes as internal
standards. RNA samples were compared via autoradiographic
analysis and normalized to the L32 housekeeping gene to ensure
that the samples were intact and uniformly loaded. All reagents
for the qRT‐PCR analysis were from Applied Biosystems, Inc.
(Foster City, CA, USA), and plate assays were read on an ABI 7700
Sequence Detector (Applied Biosystems). A summary of probe
information for each primer is provided in Supplemental
Table S1. Two micrograms of total RNA was used for each
preparation of cDNA. All cDNA preparations were generated by
random hexamer priming. Reverse transcription reactions and
PCR conditions were as previously reported.(27) The18S rRNA was
used for normalization of each target sequence. Each pooled
RNA sample was run 3 times. The fractional cycle number at
which the fluorescence passes the fixed threshold (CT values) was
used for quantification by using a comparative CT method. Mean
expression values were determined from the six measurements.
FACS analysis
For phenotypic analysis of the T‐ and B‐cell complements,
spleens, femora, and callus tissues were isolated from 10‐week‐
old wild‐type B6 and B6.MRL/Faslpr/J mice for baseline measure-
ments (before fracture) and 10 days after fracture (n¼ 5 mice per
group). Femora and adjacent callus tissues were crushed to
liberate cells into DMEM medium supplemented with 10% fetal
bovine serum, penicillin, and streptomycin. Bone fragments were
removed by sterile filtration with 70‐mm strainers (BD Bio-
sciences, San Jose, CA, USA). Splenocytes were prepared by
mechanical disruption of the spleens. For all samples, eryth-
rocytes were removedwith red blood cell lysis buffer (BioLegend,
San Diego, CA, USA), and resulting cell pellets were resuspended
in FACS staining buffer (eBioscience, San Diego, CA, USA). Cells
were stained with the following monoclonal antibodies in
presence of Fc Block (eBioscience): CD4 FITC and CD25 PE (Mouse
Regulatory T Cell Staining Kit, eBioscience), CD19 APC‐Cy7, CD3
PerCP, and CD69 Pacific Blue (BioLegend). For intracellular
staining with anti‐Foxp3 APC antibodies, the cells were first
washed, fixed, and permeabilized according to the manufac-
turer’s protocol. Dead cells were excluded based on the staining
with Zombie Aqua fixable dye (BioLegend). Data were acquired
on BD LSR II SORP (BD Biosciences). At least 100,000 single‐cell
events were acquired and analyzed with FlowJo 10.0.6 (TreeStar,
Ashland, OR, USA) for all samples. Gating determinations were
performed with the use of FMO (Fluorescence Minus One) and
isotype controls (Supplemental Fig. S1).
Statistical analysis
The data for both the control and experimental groups were
presented as means standard deviation. The difference be-
tween the two groups at each time point was evaluated by
Student’s t test, at a level of significance of p< 0.05 for the RNA
and histological analysis. For themicro‐CT assessments, the effect
of time and strain and their interactionwas established using two‐
factor ANOVAs. For the results of the torsion tests, three‐factor
ANOVAs with time, strain, condition (fractured or unfractured
femur), and the interaction between these effects were
performed. For the results of FACs analysis, three‐factor ANOVAs
with time, strain, condition (fractured or unfractured femur), and
the interaction between these effects were performed. When
applicable, a Tukey post hoc test was used to identify pairwise
differences. A significance level of p¼ 0.05 was used in all cases.
Results
Quantitative micro‐CT
Representative three‐dimensional reconstructions of longitudi-
nal half‐sections of the fracture callus are presented in Fig. 1. The
most striking feature of these comparisons was the increased
porosity in the bony calluses from the B6.MRL‐Faslpr/J mice.
Quantitative measurements of the structural and mineral
compositions of the calluses’ tissues are presented in Fig. 1B.
Both the total volume of the callus and the volume ofmineralized
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tissue in the callus were smaller in the day 35 time point
compared with the day 21 day time point and did not differ
between strains (p< 0.0001). On the other hand, the overall ratio
of volume of mineralized tissue to total callus volume was lower
in the B6.MRL‐Faslpr/J mice than in the controls at day 35
(p¼ 0.007). The tissue mineral density of the callus increased
over time, whereas the total mineral content decreased over
time in both strains (p 0.0005). The standard deviation of the
tissue mineral density decreased over time only in the control
mice (p¼ 0.0161). Identical findings were observed in the gld
mouse strain in which Fas has been completely deleted in
contrast to the lpr strain in which it is functionally defective
(Supplemental Fig. S2).
Mechanical testing
Results of the torsion tests are summarized in Fig. 2. The
fractured control femora withstood a higher maximum torque
than the B6.MRL‐Faslpr/J strain (p¼ 0.0051) (Fig. 2). None of
the other torsional properties differed between strains,
between time points, or between fractured versus contralat-
eral bones, although the fractured bones always showed
statically (p¼ 0.05) less torsional strength than the unfrac-
tured contralateral femora. The latter result suggested that by
21 days these other properties have all been regained in the
fractured bones.
Histomorphometric analysis
Callus tissues at 14 and 21 days after fracture were examined
because these time points are representative of key transition-
al points in the resorption of the mineralized cartilage (day 14)
and the maximal period of primary bone formation (day 21).
Qualitatively, the B6.MRL‐Faslpr/J calluses looked larger and
had more cartilage tissues present at 14 days after facture with
small remnants of cartilage tissue still observed at 21 days after
Fig. 1. Callus microstructure at 21 and 35 days after fracture as assessed bymicro‐CT. (A) Representative renderings on days 21 and 35 days after fracture.
The reconstructed images were cut longitudinally to show the internal microstructure. (B) Graphical analysis of the structural micro‐CT measurements of
fracture calluses at 21 and 35 days after fracture. (C) Graphs showing characteristics of differences based on mineral content. The error bar is SD.
a¼ significance by time; b¼ significant interaction by time and strain; c¼difference by strain at a single time point; d¼difference by time for a single
strain. Significance was at p< 0.05.
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fracture compared with the control specimens (Fig. 3A). Higher
magnification of regions of trabecular tissues at 21 days after
fracture provided corroborating data to the micro‐CT findings,
showing that there was less trabecular tissue at this time
(Fig. 3B). Quantitative measures of the total callus cross‐
sectional areas for both control and B6.MRL‐Faslpr/J strain were
higher in day 14 after fracture calluses (p< 0.0001) than day 21
calluses, whereas calluses from the B6.MRL‐Faslpr/J strain had a
greater area than the control calluses at both time points
(p< 0.0001). The measured area of bone in the calluses did not
change between days 14 and 21; however, it was significantly
less in the B6.MRL‐Faslpr/J strain regardless of the time point
(p< 0.0013). In contrast, the amount of cartilage tissue was
greater in the B6.MRL‐Faslpr/J strain (Fig. 3C) at both time
points. Separate assessments based on the percentages of
tissue compositions are presented in Table 1, and a summary of
the statistical analysis of interaction between time and strain
for each of the separate measurements is presented in this
table.
Analysis of cartilage and bone cell mRNA expression
Molecular assessments of mRNA expression for a number of
families of different genes were carried out to further determine
how the lpr mutation led to the changes in tissue compositions
that were seen in the fracture specimens. The mRNA expression
that encodes a group of extracellular matrix proteins, which
would be indicative of both cartilage and bone development and
differentiation, were assessed by RPA. A representative autora-
diograph of an RPA of selected extracellular matrix protein
mRNAs across the time course of fracture healing is seen in Fig. 4.
The graphic results for four of the expressed mRNAs that were
examined by the RPA are shown at the bottom of the figure. The
expression of all four bone‐associated mRNAs (type I collagen,
osteocalcin, bone sialoprotein, and osteopontin) all showed
increased expression in B6.MRL‐Faslpr/J mice, with all of them
having statistically higher levels of expression at 21 and 28 days
after fracture (p¼ 0.045). Intermediate‐ and early‐late‐stage
markers of osteogenesis as determined by expression of
osteopontin and BSP also showed both an early (day 3) and
later peaks in expression (day 14) and also showed higher levels
of expression in the B6.MRL‐Faslpr/J on days 21 and 28.
Chondrogenesis was assessed by examining the expression of
collagen type II (Col2A1) and collagen type X (Col10A1). Both of
these mRNAs peaked at day 10 in the control calluses, whereas
the Col10A1 peak was broader and lagged that of Col2A1 in the
B6.MRL‐Faslpr/J calluses.
Assessment of tissue resorption and remodeling
Osteoclast numbers in the calluses were next examined as a
measure of tissue resorption and remodeling. Low‐magnification
images of the total cross‐sectional areas of the callus provide a
global qualitative assessment of number of osteoclasts within
the tissue (Fig. 5A, upper panels). Although callus tissues from
both the control and B6.MRL‐Faslpr/J strain had observable
amounts of TRAP‐positive cells, the B6.MRL‐Faslpr/J strain
appeared to show more activity. Higher magnifications showed
individual TRAP‐positive multinucleated cells both on surfaces of
new primary bone as well as on the surfaces of mineralized
cartilage (Fig. 5B). Consistent with our previous studies, the
greatest number of osteoclasts were seen during the period of
resorption of the mineralized cartilage (day 14) and decreased
with time (p< 0.0001), and this interaction between time and
strain was significant (p< 0.0024). The Tukey post hoc test
showed that the day 14 B6.MRL‐Faslpr/J strain had a higher
osteoclast count than any of the other specimens that had been
analyzed (Fig. 5C). An overall summary of all of the histomor-
phometric measurements and indices and their statistical
significance is presented in Table 1.
A selected set of markers associated with the regulation and
progression of osteoclast differentiation were measured
(Fig. 5D). The ratio of RANKL to OPG was determined because
this ratio is the central factor that controls osteoclastogenesis.
Fig. 2. Results of the torsion tests. (Left panel) Comparison of torsional strength (in Nm) of the calluses from control and B6.MRL‐Faslpr/J mice at 21 and
35 days after fracture and of contralateral femora from the two genotypes at matching time points. (Right panel) Comparison of torsional rigidity (in
Nmm2/rad) among these same groups. e¼ significance by strain. The error bar is SD. Significance was at p< 0.05.
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During the initial periods of endochondral bone formation,
there was no difference for the mRNA expression ratio in the
two strains, but by day 10 the B6.MRL‐Faslpr/J showed a higher
ratio than observed in the controls and this higher ratio then
persisted throughout the period of coupled remodeling of
primary bone at 21 and 28 days after fracture. An assessment of
M‐CSF, the other major regulator of osteoclast development,
showed a more prolonged period of later expression slightly
preceding and then paralleling the higher RANKL/OPG ratio.
The fold change in both TRAP and calcitonin receptor
expression for both strains sharply increased at day 10, after
which the levels of expression remained elevated until day 21,
when they began to return to its baseline. Although TRAP
expression levels were greater at 14 days in the B6.MRL‐Faslpr/J
than the control, this difference was not significant. On the
other hand, calcitonin receptor expression peaked earlier and
was lower in the control samples and was statistically higher at
both 21 and 28 days after fracture in the B6.MRL‐Faslpr/J strain
(p< 0.05). It is interesting to note that because calcitonin
receptor expression is associated with fully mature osteoclasts,
its more prolonged levels of expression would be suggestive
that these cells have a longer life span in the B6.MRL‐Faslpr/J
strain.
Assessment of the inflammatory state and T‐cell activity
during endochondral bone formation
To assess if the autoimmune phenotype of the B6.MRL‐Faslpr/J
strain affected endochondral bone formation or bone turnover
during fracture healing, several different pro‐ and anti‐
inflammatory cytokines that have been shown to have altered
expression during an active autoimmune state were assessed
(Fig. 6A). As expected, these data showed that the expression
of TNF‐a, IL‐1b, and IL‐17F all were constitutively higher in the
B6.MRL‐Faslpr/J. In contrast, cytokines that would prevent the T
cells from progressing to a Th1 phenotype (IL‐10, IL‐17A) were
elevated in the mutant mice, whereas those that have been
shown to inhibit Th17 development toward an iTreg (IL‐6 IL‐
23) also showed diminished initial induction after fracture in
the B6.MRL‐Faslpr/J mice.(29) Using CD4 as a general assess-
ment of T cell numbers also showed lower levels of CD4 mRNA
initially after fracture in the wild‐type mice. A comparison of
Fig. 3. Histological analysis of fracture calluses at days 14 and 21 days after fracture (safranin‐O and fast green). (A) Representative micrographs from 14
and 21 days after fracture. (Top panel) Composite images of fracture calluses (100 magnification). (B) Representative micrographs of trabecular and
medullary tissues at 21 days after fracture (200magnification). (C) Graphic analysis showing the total callus area, total cartilage area, and total bone areas
inmm2 as calculated from the histomorphometric analysis for the control and B6.MRL‐Faslpr/J strains at days 14 and 21 days after fracture. Themean value
from 5 representative sections per callus (a total of 5 calluses were used per time point) are shown. The error bar is SD. Group differences are as denoted
in Fig. 1. Statistical comparisons between strains times and interactions are as denoted by letters and are as presented in Figure legends 1 and 2.
Significance was at p< 0.05.
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these cytokine patterns across the time course of fracture
healing further showed that there was reciprocal down-
regulation and upregulation of the cytokines that drive Th1
and iTreg differentiation, respectively, during the period of
cartilage formation in both B6.MRL‐Faslpr/J and wild‐type
callus tissues.
As a second assessment of the autoimmune state, FACS
analysis was performed to determine the T‐cell subset
distribution in the spleen and femora at both the baseline
before fracture and at 10 days after fracture. At the later time
point, contralateral femora were further compared with the
callus tissues of the fractured bones. These results revealed that
B6.MRL‐Faslpr/J mice had higher levels of Treg cells within both
the bone and spleen at baseline before fracture (Fig. 6B, C). In
both wild‐type mice and B6.MRL‐Faslpr/J mice, fracture
appeared to systemically increase Treg percentages, 60%
and 30%, respectively, within both the fractured and
contralateral femur (Fig. 6B) while having no effect on the
numbers of these cells in the spleen (Fig. 6C, Supplemental
Fig. S1). The percentage of activated T cells in the bone at the
baseline was less in B6.MRL‐Faslpr/J mice than in wild‐typemice.
After fracture, the Treg levels decreased in the callus tissues of
the wild‐type mice within the callus tissues while remaining
unchanged in the B6.MRL‐Faslpr/J mice. Unlike Treg cells that
showed systemic changes in the contralateral bones, the
percentage of activated T cells, as determined by CD69
expression, remained unchanged for both wild‐type and B6.
MRL‐Faslpr/J mice within the unfractured femur. Further, within
the spleen, the percentage of activated T cells was always
higher in the B6.MRL‐Faslpr/J mice both at the baseline and at
10 days after facture, and these levels are unchanged in
response to fracture. Analysis of the percentage B cells in bone
tissues showed no changes either between strains of mice or in
response to fracture. In contrast, the percentage of these cells in
the spleen was less in the B6.MRL‐Faslpr/J mice at both the
baseline and after fracture (data not shown).
Assessment of tissue apoptosis
In the last analysis that is presented, a qualitative assessment of
the number of cells that were primed to undergo apoptosis was
carried out using immunohistological staining for the expression
of caspase 3. We examined the callus tissues at 14 days after
fracture because both cartilage tissue and high levels of
osteoclasts were observed at this time (Fig. 7). An examination
of comparable areas of cartilage tissue in the B6.MRL‐Faslpr/J and
wild‐type mice showed that there were many more chondro-
cytes showing strong green fluorescent‐staining cells for the
presence of the capsase 3 in the wild‐type callus tissues than in
the B6.MRL‐Faslpr/J tissues. These images are depicted in the
upper panels of the figure. We next carried out sequential
reactions first for TRAP and then with caspase 3. Those
osteoclasts that showed colocalization with caspase 3 stain
orange and are those osteoclasts that would be primed to
underage apoptosis. Like the chondrocytes, many more positive
osteoclasts were seen in the control samples. These images are
depicted in the lower panels of Fig. 7.
Discussion
Both similar and different features in the progression of fracture
healing were observed in mice deficient in Fas (B6.MRL‐Faslpr/J)
in comparison to mice lacking TNFR signaling. Unlike fracture
healing in the absence of TNFR signaling, no delays in the
initiation of chondrogenesis was observed. These conclusions
are based on two findings: 1) there was no change in the
temporal expression of both chondrogenic and osteogenic
mRNA expression levels found in the callus tissues of B6.MRL‐
Faslpr/J mice at the earliest times points, suggestive that stem cell
recruitment was normal during the initial periods of fracture
healing; and 2) the callus tissues at day 14 in the B6.MRL‐Faslpr/J
mice were larger, which suggests that the formation of the initial
tissue analogue was unaffected by this type of systemic
Table 1. Mean Values for the Histomorphometric Measurements and Indices
Measurement or index Control Day 14 Lpr Day 14 Control Day 21 Lpr Day 21
Total callus area (mm2)
Mean 8.68 12.7 6.98 9.51
SD 3.45 2.87 3.07 2.62
Time p< 0.00001
Strain p< 0.0001
Time strain p¼ 0.2040
Percentage of bone per callus
Mean 0.123 0.062 0.236 0.076
SD 0.071 0.0052 0.0403 0.0058
Time 0.1292
Strain 0.0096
Time strain 0.2389
Percentage of cartilage per callus
Mean 0.065 0.224 0.002 0.007
SD 0.011 0.011 0.0006 0.001
Time p< 0.0001
Strain p< 0.0001
Time Strain p< 0.0001
The p values are shown for two‐way ANOVA with the effects of time, strain, and the interaction of time and strain.
Statistical significance at p< 0.05.
SD¼ standard deviation; Control¼C57BL/B6; lpr¼ B6.MRL/Faslpr/J.
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autoimmune disease. Thus, these results also lend credence to
the hypothesis that part of the biological functions of TNFR
signaling during early tissue repair is to facilitate early stem cell
recruitment, consistent with other results that show that very low
doses of locally applied TNFa promote fracture healing.(5)
Although the loss of functional Fas signaling does not appear
to effect early callus development, distinct differences in the
progression of fracture healing were observed during the
periods of cartilage resorption and the remodeling of the
primary bone. These results are similar to fracture healing in the
TNFR‐deficient mice, which also show delayed progression
through the endochondral bone formation period, in that higher
percentages of cartilage tissues are found in the calluses of the
B6.MRL‐Faslpr/J mouse strain through the 21‐day‐after‐fracture
period relative to the controls. As described above, because
neither the time course nor the amounts of the cartilage mRNA
Fig. 4. Analysis of expression of bone‐ and cartilage‐specific mRNAs. (A) Representative autoradiographic image of the RPA products as resolved on a 6%
denaturing sequencing gel. Matrix genes are depicted. Days after fracture, mouse strain, and positions of each protected gene are denoted in the figure.
L32 (mouse ribosomal protein) was used as an internal standard. (B) Graphic analysis of the relativemRNA expression levels of four of themRNAs indicative
of either cartilage or bone tissue development obtained from RPA analysis over the time course of fracture healing. The nature of each of themRNAs that is
presented is indicated in the legend of the figure. Data presented aremean values from n¼ 4 gels, and error bars areþ SD. Significance between the two
strains at p< 0.05.
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expression were initially different, the greater accumulation in
cartilage tissues was not the result of greater levels of cartilage
development. The statistically higher levels of type X collagen
mRNA expression at day 14 after fracture also suggest that the
chondrocyte remained in a viable hypertrophic state for a longer
period. These results are similar to our previous finding for mice
lacking TNFR signaling that showed that increased cartilage
contents were the result of delayed cartilage resorption. Such
results are consistent with the results that showed a smaller
number of chondrocyets stained for caspase 3, which correlates
with the suggestion that loss of Fas leads to delayed cartilage
apoptosis. Although loss of Fas signaling delayed cartilage
resorption, these tissues were eventually removed, suggesting
that Fas independently acts in parallel with TNFa to mediate
apoptosis, which would be consistent with the persistent higher
levels of TNFa expression found in the B6.MRL‐Faslpr/J mouse
strain. Alternatively, both these extrinsic death receptors may be
working in tandemwith other intrinsicmechanisms thatmediate
chondrocyte apoptosis. In this regard, it is of interest to note that
chondrocyte apoptosis during hypertrophic development also
appears to be mediated by activation of intrinsic mitochondria
mechanisms(30) in which mitochondrial DNA damage and
intrinsic activation of apoptosis is caused by pro‐inflammatory
cytokines in human OA chondrocytes.(31)
In contrast to the delayed resorption of the cartilage tissues
within the callus, both histological and micro‐CT analysis of the
callus tissues at later times showed statistically decreased
amounts of accumulated mineralized bone tissues. The assess-
ment of the biological mechanisms that mediated the dimin-
ished accumulation of bone showed that this was attributable to
increased bone turnover. This conclusion was based both on the
significantly higher numbers of TRAP‐positive multinucleated
cells that lined the bone and mineralized cartilage surfaces in B6.
MRL‐Faslpr/J fracture calluses and the greater levels of expressed
osteoclast mRNAs. Because themeasured area of bonewas lower
in the B6.MRL‐Faslpr/J strain, the amount of osteoclasts per area
of bone and cartilage was even more exaggerated in B6.MRL‐
Faslpr/J than control calluses. These results suggest that optimal
mineralized cartilage resorption must either be linked to
chondrocyte apoptosis or be inhibited by viable chondrocytes.
Fig. 5. Analysis of osteoclast activity in fracture calluses. (A) Panoramic histological assessments of local osteoclast activity within callus tissues based on
TRAP 5b staining within 14‐ and 21‐day callus tissues. Composite images of fracture calluses (40 magnification). (B) Osteoclast morphology on bone/
cartilage surface for each strain of mouse (400 magnification). (C) Osteoclast counts per unit total callus area. Osteoclast counts were determined as
described inMaterials andMethods. Numbers are presented per average area of entire callus and per area of bone surface. (D) Analysis of the expression of
osteoclast and proresorptive cytokinemRNAs. Graphical representation of the temporal patterns and relative levels ofmRNA expression for variousmRNAs
associated with osteoclasts and the regulation of their expression. mRNA expression levels were determined by qRT‐PCR. Days after fracture is denoted,
and strain of mice is the same as denoted in the legend in Fig. 4. The nature of eachmRNA that is assessed is indicated in the figure. The overall expression
of RANKL andOPG are not presented, rather the ratio of the expression of thesemRNAs. Data presented aremean values from n¼ 6 replicates determined
from two pools of mRNAs per time point. The error bars areþ SD. Significance between the two strains at p< 0.05.
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This conclusion is consistent with recent findings that show that
cartilage destruction in polychondritis is induced not only by
perichondral inflammation but also by the expression of
proteolytic enzymes by the chondrocytes themselves in
association with the induction of apoptosis.(32) Our results would
also be consistent with this finding and further suggest that
proteolytic completion of the mineralized cartilage resorption
takes place only when the chondrocytes undergo their
apoptosis. In addition, these results suggest that mineralized
cartilage resorption must be only partially mediated by
osteoclasts given that these cells show no delay in their
recruitment in the B6.MRL‐Faslpr/J fracture calluses and are
actually present in greater numbers in themutant mouse tissues.
The comparison of the control and B6.MRL‐Faslpr/J mice
fracture suggests that the remodeling phases in which primary
bone was being replaced were greatly elevated. This conclusion
was based both on multiple findings, including the histological
analysis of the trabecular bone parameters in B6.MRL‐Faslpr/J
calluses, which had fewer trabeculae that were thinner with an
overall greater spacing (more porous); the diminished bio-
mechanical competency of the B6.MRL‐Faslpr/J calluses at
35 days after fracture; and the elevated numbers of TRAP‐
positivemultinucleated cells that were found at later times in the
callus tissues. It is interesting to note that the increased numbers
of TRAP‐positive cells were accompanied by a consistently
elevated level of mRNA expression for all of the osteoblast
markers that we assayed, including those for both early (Col1a1,
OPN) and later (BSP, OC) marker genes for osteoblast differenti-
ation. There was no evidence, though, of increased osteoid
production, suggesting that either the osteogenic cells are
expressing higher levels of their gene products or that these cells
are rapidly turning over and do not form substantial amounts of
new osteoid. This later conclusion is consistent with recent
studies that have shown that most osteoblast cells are relatively
short lived and that they arise from an actively mitotic stem cell/
progenitor pool.(33)
Separatemechanisms effecting both initial osteoclastogenesis
and prolongation of osteoclast activity and life span may be
evoked for the greater numbers of osteoclasts, which were
observed in the B6.MRL‐Faslpr/J mouse. Data consistent with
Fig. 6. Assessments of inflammatory state and T‐cell activity. (A) Graphical representation of the expression of the temporal patterns and relative levels of
mRNA expression of select pro‐ inflammatory and T‐cell regulatory cytokines as determined by qRT‐PCR. Days after fracture are denoted, and strain ofmice
is the same as denoted in Fig. 4. The nature of each mRNA that is assessed is indicated in the figure. Data presented are mean values from n¼ 6 replicates
determined from two pools of mRNAs per time point. The error bars areþ SD of the 6 replicates from the two pools. Significance between the two strains
for that time point p< 0.05 based on the comparisons of the replicates. (B) Flow cytometric analysis of Tregs and activated T cells in femoral bones at
baseline before fracture and in both the contralateral (Cntl) unfractured and fracture (Fx) bone at 10 days after fracture. Tregs were identified as the
percentage of CD25þ Foxp3þ of all live CD3þCD4þ cells, and activated T cells were percentage CD69þ of all CD3þCD4þ cells. Intragroup:
difference (p< 0.05) at day 0 and after‐fracture day 10 in either WT or LPR strains. Intergroup: #difference in mice between WT and LPR strains. (C) Flow
cytometric analysis of Tregs and activated T cells in spleens at baseline before fracture and at 10 days after fracture in both WT and LPR strains. Gating
strategy and labeling are the same as in (B). A complete summary of the findings for the ANOVA statistical analysis of these data is presented in
Supplemental Tables S3–S5.
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greater levels of initial osteoclastogenesis are related to both the
earlier and higher levels of TRAP mRNA expression that were
observed in the callus tissues for the B6.MRL‐Faslpr/J mouse. It is
interesting to note as well the consistent and statistically higher
levels of TNFa mRNA expression and RANKL to OPG ratios that
were observed in mutant mice. Mechanistic studies have shown
that TNFa is a proresorption cytokine that leads to bone
destruction,(34) with some studies showing TNFa inducing bone
resorption via its indirect stimulation of both RANKL and M‐CSF
with commensurate downregulation in OPG expression.(35–37)
Other mechanisms have shown that pathologically high TNFa
levels lead to direct induction of osteoclastogenesis at the level
of blood osteoclast precursors (OCP),(38) whereas other studies
have shown that high levels of TNFa directly increases TRAP‐
positive cells in vitro.(39,40) In context of themouse lprmutation, it
is interesting to note that loss of Fas antigen receptor leads to the
development of toxic shock syndrome much faster than in
normal mice,(41) with increased expression of TNFa and a
number of other pro‐inflammatory cytokines.(42) The direct role
of Fas/FasL system in osteoclastogenesis and in mediation of
osteoclast apoptosis has now been shown in numerous studies.
The interaction of FasL and Fas on osteoclast precursors was
shown to increase osteoclastogenesis.(43) In many other studies,
the role of Fas/FasL system has been shown to be crucial in
mediating apoptosis in osteoclasts and controlling the longevity
of osteoclasts,(44,45) whereas other studies have shown that
induction of Fas by estrogen is a central protective element
against the development of bone loss in female animals.(10,46)
Abnormalities in the immune cell function have long been
associated with osteolytic bone conditions such as rheumatoid
arthritis. An assessment of both T‐cell activation and T regulatory
cells in the wild‐type and B6.MRL‐Faslpr/J mice was carried out to
elucidate the role of T‐cell subsets during cartilage resorption
and bone remodeling. The findings of this study suggest B6.MRL‐
Faslpr/J mice have an active autoimmune state based on the
higher percentage of activated T cells and Treg cells in both the
spleen and bones at the baseline before fracture. It is interesting
to note, however, during the period of active cartilage tissue
formation after fracture that the percentage of Treg cells was
systemically increased specifically in bone tissues based on their
increased numbers within both fractured and unfractured bones.
In contrast, the percentage of these cells remained unchanged in
the spleen. These findings taken together with the 100‐ to 200‐
fold induction of IL‐17A suggest that these cells are specifically
iTreg cells and that cartilage formation produces factors that
promote their formation within bone tissues. This interpretation
is further consistent with the decreased or unchanged numbers
of activated T cells in callus tissues in the either wild‐type or B6.
MRL‐Faslpr/J mice, respectively. In this context, these results are
similar to the paradoxical findings showing diminished cartilage
destruction in a collagen‐induced arthritis (CIA) model compar-
ing DBA‐lpr/lpr with DBA wild‐type mice, even though these
mice have a more robust inflammatory state. These authors
concluded that the lack of the expected severe disease in DBA‐
lpr/lpr mice is because of a local attenuating effect of the Fas
mutation in pathological processes involving resident joint cells.
They further attributed this to alterations in either synovial cells
or T‐cell populations in the joint and not to the role that Fas plays
in mediation of chondrocyte apoptosis.(47) Such findings in
conjunction with ours suggest that within cartilage tissues, iTreg
cells are protective to cartilage tissue destruction.
Our results also match most of the findings of Nam and
colleagues,(48) who examined fracture healing in Rag1‐/‐ mice
Fig. 7. Immunohistological analyses of chondrocyte and osteoclasts
within 14‐day callus tissues that show caspase 3 reactivity. Under
fluorescent excitation, caspase antibody staining is bright green and red
blood cells are autofluorescent and appear as small bright green cells,
whereas backgrounds appear as defuse light green. DAPI staining is
bright blue and stains the nuclei of cells. Under fluorescent excitation,
TRAP staining is red and double‐stained cells with caspase stain orange.
Under light field, TRAP cells appear as pink‐red cells. (Upper panels)
Sequential set of micrographs showing fluorescent images of chon-
drocytes that are reactive with anti‐caspase 3 antibody in control (CON)
and Lpr strain of mice (LPR). A low‐magnification fluorescent image and
higher‐magnification image from the same field superimposing the
fluorescent on light level photomicrograph are presented. Cells were co‐
reacted with DAPI to identify the nuclei of the individual cells in the
micrographs. (Lower panels) Sequential set of micrographs showing light
level and fluorescent images of TRAP‐positive osteoclasts. Those cells
that are reactive with anti‐caspase 3 antibody are stained orange, and
borders of these cells show a green edge. Cells were co‐stainedwith DAPI
to identify the individual cells in the micrographs. Magnification is
indicated in each image.
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that have deficient T‐ and B‐cell function. Although our results
showed similar increases in the expression of IL‐6, IL‐23, and IL‐10
in the wild‐type mice immediately after fracture, we did not see
initial elevation in IL‐17F at 3 days after fracture. With the
exception of TNFa, our findings showed decreased expression
for these pro‐inflammatory cytokines in B6.MRL‐Faslpr/J similar to
that seen in the Rag1‐/‐ mice. Although these results would
appear contradictory in relationship to an active autoimmune
state, they would be consistent with the increased percentages
of iTreg cells and be suggestive of a compensatory response to
the systemic autoimmunity during cartilage tissue formation. In
this regard, recent studies by Adamik and colleagues(49) showed
that PGE2 and IL‐23 plus IL‐1b differentially regulate Th17
cytokine expression and synergize to induce IL‐17A but not IL‐
17F, whereas IL‐23 plus IL‐1b in the absence of PGE2
preferentially induce IL‐17F expression. Consistent with these
observed combinations of cytokines that differentially regulate
the expression of IL‐17A and IL‐17F are the findings from our
prior studies that have shown that both Cox2 expression levels
and PGE2 levels in the callus are induced during the period of
cartilage tissue formation.(50,51)
It is interesting to note that one of the major complications in
SLE patients is osteoporosis.(52) The data from our studies are
consistent with human studies that have shown significant
trabecular and cortical bone loss,(53) as well as other studies that
have shown osteoporotic vertebral fractures in up to 20% of
patients with SLE.(54) Other studies have found an association
between SLE disease damage and low bone mineral density
(BMD) T‐scores.(55) Although many of these studies are carried
out in patients with prolonged SLE, a question of the etiology of
the osteoporotic disease is related to the use of glucocorticoids
and cyclophosphamide to manage these diseases that by
themselves lead to bone loss.(52) In light of the question of the
actions of these therapeutics on bone loss independent of the
primary actions of SLE, our animal studies would suggest that
the systemic SLE pathology itself leads to elevated turnover of
bone because our animals do not receive any type of
pharmacological treatments during the course of their bone
healing. In this regard, our findings, as they relate to the elevated
expression of IL‐17F at later periods after cartilage resorption
when only coupled bone remodeling is taking place, are
consistent with a high turnover state of osteoporosis. This is
based on recent findings of Nam and colleagues,(48) who
showed that IL‐17F is highly stimulatory of osteogenesis, as well
as other studies that show that it supports osteoclastogenesis by
the stimulation of mesenchymal and osteoblast production of
RANKL and M‐CSF.(56) This conclusion is also consistent with a
number of recent studies that have shown that patients who
have never received glucocorticoids were observed to have a
lower hip bone mineral density than controls, suggesting that
SLE per se might induce bone loss.(53) Finally, similar conclusions
as ours on the primary actions of the SLE on loss were reached in
developmental studies within this same mouse model (B6.MRL‐
Faslpr/J) as we are using, which showed that these animals
developed low bone mass index phenotype,(57) although the
molecular mechanism that led to low bone mass had not been
identified in these early studies.
In conclusion, our data show that loss of Fas activity does not
effect endochondral bone formation. Although the number of
TRAP‐positive cells per area of bone and cartilage was greater in
the B6.MRL‐Faslpr/J, the rate of cartilage resorption was
codependent on chondrocyte apoptosis. During the later periods
of coupled remodeling of the primary bone, the B6.MRL‐Faslpr/J
fracture calluses are weaker andmore porous. This corresponded
to a higher ratio of RANKL/OPG at after‐fracture days 21 and 28.
We determined there were both higher osteoclast activity in the
B6.MRL‐Faslpr/J and more osteoblast activity based on more
expression of extracellular matrix proteins at later stages in the
fracture repair. We conclude from these data that there was a
state of high‐turnover osteoporosis occurring in the B6.MRL‐
Faslpr/J mouse.
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